Who is sponsoring NCT05880654?

NCT05880654 is sponsored by Fayoum University.

What drugs are being tested in NCT05880654?

Interventions in NCT05880654: Scaling & root planning.

What condition does NCT05880654 study?

NCT05880654 studies Generalized Periodontal Disease, AVDC Stage 3.

Is NCT05880654 still recruiting?

NCT05880654 is currently completed. Last updated 30 May 2023.

Last reviewed 2023-05-30 · How we verify

NCT05880654

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IL-39 & IL-35 Gingival Crevicular Fluid Levels in Diabetic Patients With Generalized Periodontitis

Completed NA Last updated 30 May 2023

What this trial tests

NA trial testing Scaling & root planning in Generalized Periodontal Disease, AVDC Stage 3 in 57 participants. Completed in 15 May 2023.

Timeline

1 January 2023

Primary endpoint
30 April 2023

15 May 2023

Quick facts

Lead sponsor	Fayoum University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	1 January 2023
Primary completion	30 April 2023
Estimated completion	15 May 2023
Sites	2 locations across Egypt

Drugs / interventions tested

Scaling & root planning

Conditions studied

Generalized Periodontal Disease, AVDC Stage 3 — all drugs for Generalized Periodontal Disease, AVDC Stage 3 →

Sponsor

Fayoum University

Who can join

Adults 35 to 50, any sex, with Generalized Periodontal Disease, AVDC Stage 3. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The sudy was aiming to assess and compare GCF levels of IL-39 \& IL-35 in gingival crevicular fluid and to correlate the relationship between different patient groups before and after non-surgical therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

IL-39 and IL-35 gingival crevicular fluid levels in diabetic patients with generalized periodontitis.
Hassan SS, Abdelkawy M, Shaker OG, Tarrad NAF. · · 2024 · cited 5× · PMID 38286978 · DOI 10.1007/s00784-023-05484-3

Verify or expand the search:

Other Fayoum University trials

Trials by the same sponsor.

NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05880654 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fayoum University
Last refreshed: 30 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05880654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing